Hybrigenics SA Logo

Hybrigenics SA

Provider of technologies for studying molecular interactions and antibody selection.

ALHYG | PA

Overview

Corporate Details

ISIN(s):
FR0004153930
LEI:
9695003KQD0XMJYDX764
Country:
France
Address:
850 BOULEVARD SEBASTIEN BRANT, 67400 ILLKIRCH-GRAFFENSTADEN

Description

Hybrigenics Services is a specialized provider of technologies for studying molecular interactions. Its core offering is the ULTImate Y2H™ platform, a comprehensive Yeast Two-Hybrid system used to discover protein-protein interactions, as well as interactions with DNA, RNA, and small molecules. This technology is applied to drug discovery for target deconvolution and identifying molecular glues. A second key service is the Hybribody platform, which leverages a proprietary synthetic library for the custom selection, validation, and optimization of single-domain antibodies (VHHs/Nanobodies). The company serves clients in fundamental research, pharmaceutical R&D, and agroscience.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-12-09 09:00
DMS Biotech Horizon 2020 Phase 1
French 423.8 KB
2019-10-31 18:15
Hybrigenics : Report de la publication des comptes semestriels 2019
French 276.7 KB
2019-10-17 10:30
Franchissement de seuils
French 272.0 KB
2019-10-15 18:00
Prise de contrôle par DMS Group
French 299.4 KB
2019-10-09 18:30
Prise de contrôle d'Hybrigenics par DMS : obtention de la dérogation de l'AMF
French 286.1 KB
2019-09-20 17:15
Assemblée générale mixte d'Hybrigenics du 20 septembre 2019 : approbation de to…
English 289.7 KB
2019-09-19 18:00
Assemblée générale mixte du 20 septembre 2019 : quorum atteint
French 288.7 KB
2019-09-06 17:45
Assemblée générale mixte d'Hybrigenics : seconde convocation le 20 septembre 20…
French 301.7 KB
2019-07-29 18:00
Hybrigenics : Convocation à une assemblée générale mixte le 6 septembre 2019
French 456.9 KB
2019-02-07 18:00
Hybrigenics et DMS Group entrent en négociation exclusive
French 185.8 KB
2019-01-14 08:00
Hybrigenics reçoit une offre de prise de contrôle
French 603.0 KB
2018-12-20 18:00
Hybrigenics : Convocation à une nouvelle assemblée générale mixte le 15 janvier…
French 280.1 KB
2018-12-04 18:30
Hybrigenics demande à Moonstone Investments de clarifier son offre
French 74.1 KB
2018-12-03 18:00
Hybrigenics : comptes consolidés semestriels 2018 établis en valeur de liquidat…
French 308.7 KB
2018-03-26 19:15
Publication d'une activité antivirale
French 381.1 KB

Automate Your Workflow. Get a real-time feed of all Hybrigenics SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hybrigenics SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hybrigenics SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.